Featured Research

from universities, journals, and other organizations

More evidence that allergies may help in fighting brain tumors

Date:
October 27, 2011
Source:
Brown University
Summary:
Subjects with somewhat elevated levels of antibodies produced to fight allergens were less likely to go on to develop brain tumors, according to a new study. The study adds to evidence from prior studies, but some questions still remain.

A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system's response to allergies may reduce the risk of developing deadly brain tumors.

"These results suggest that there is something different about the immune response to tumor cells in people with allergies."People with somewhat elevated blood levels of immunoglobulin E (IgE), antibodies that carry out the body's immune response to allergens, were significantly less likely to develop gliomas, and those who did survived somewhat longer, than those with clinically normal IgE levels, according to the study by a team of researchers at Brown University and several other institutions in the United States and Europe.

"These results suggest that there is something different about the immune response to tumor cells in people with allergies," said corresponding author Dominique Michaud, associate professor of epidemiology in the Public Health Program at Brown University. "In terms of fighting the cancer or preventing it from growing, people who have allergies might be protected. They might be able to better to fight the cancer."

Questions answered, questions raised

The new study employed a methodology that addresses questions raised by previous studies that have also reported similar associations between IgE, or allergy symptoms, and brain tumors. Instead of asking people who have or have not been diagnosed with brain tumors to describe their allergy history or to take IgE tests, the study delved into the detailed records of tens of thousands of people who participated in four broad-based health studies: the Physicians' Health Study, the Nurses' Health Study, the Women's Health Study, and the Health Professionals Follow-up Study.

Such "prospective" analysis of samples collected from patients before they were diagnosed or treated for brain tumors, allowed the researchers to measure the association between IgE and brain cancer risk without worry that the IgE levels were affected by the course of the disease and treatments for it.

"This is really the first study to look at total IgE levels collected prior to disease," Michaud said. "This is important in being able to determine whether this is a causal effect."

Although the pool of patients in the four studies was large, the actual number of relevant cases was small. Only 169 people with stored plasma subsequently developed brain tumors. They were matched with 520 control subjects (otherwise similar people who did not develop tumors). The small numbers blunted some of the study's results.

For example, the researchers found a statistically significant reduction in glioma risk among people with borderline elevated IgE levels (in a range of 25,000 to 100,000 units per liter), but not for people with even higher levels of IgE. Michaud acknowledged that further research would be needed to explain why the protective effect couldn't be measured in people with the highest IgE levels.

Ultimately, Michaud said, by strengthening the evidence that allergic immune response may affect brain tumors, the study may encourage cancer researchers to focus on the biological mechanisms underlying this association and provide insight into the disease and its treatment.

In addition to Brown, other institutions with affiliated authors of the paper include Imperial College in London, Brigham and Women's Hospital in Boston, and the Harvard University School of Public Health in Boston.

The National Institutes of Health funded the study.


Story Source:

The above story is based on materials provided by Brown University. Note: Materials may be edited for content and length.


Journal Reference:

  1. F. C. F. Calboli, D. G. Cox, J. E. Buring, J. M. Gaziano, J. Ma, M. Stampfer, W. C. Willett, S. S. Tworoger, D. J. Hunter, C. A. Camargo, D. S. Michaud. Prediagnostic Plasma IgE Levels and Risk of Adult Glioma in Four Prospective Cohort Studies. JNCI Journal of the National Cancer Institute, 2011; DOI: 10.1093/jnci/djr361

Cite This Page:

Brown University. "More evidence that allergies may help in fighting brain tumors." ScienceDaily. ScienceDaily, 27 October 2011. <www.sciencedaily.com/releases/2011/10/111020025754.htm>.
Brown University. (2011, October 27). More evidence that allergies may help in fighting brain tumors. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/10/111020025754.htm
Brown University. "More evidence that allergies may help in fighting brain tumors." ScienceDaily. www.sciencedaily.com/releases/2011/10/111020025754.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins